Time filter

Source Type

Sun X.,Beijing Normal University | Sun X.,Hospital of Academy of Military Medical science | Guo M.,Hospital of Academy of Military Medical science | Sun Q.,Hospital of Academy of Military Medical science | And 7 more authors.
Leukemia Research | Year: 2014

Aim: To study microchimerism's role and function after microtransplantation and identify novel genetic markers for microchimerism detection. Methods: Analyzing microchimerisms from patients microtransplanted to determine the presence of GSTT1, GSTM1, SRY and other genetic markers by real-time PCR. Results: Microchimerism could be detected for a short time after microtransplantation simultaneously with hematopoietic recovery. In conclusion, microchimerism might accelerate hematopoietic recovery and GSTT1 and GSTM1 genes could be used as genetic markers to differentiate donor cells. Discussion: Microchimerism could exist for a short time after microtransplantation and appears to function in hematopoietic recovery. According to published reports, cytokines secreted from microchimerisms could be detected in recipients and exhibit some function on the host. Therefore, cytokines secreted from donor cells are hypothesized to accelerate hematopoietic recovery. The evidence to prove a longer existence for microchimerism is insufficient and needs supports by additional experiments; however, we cannot deny its existence just because of the limited sensitivity of methods. © 2014 Elsevier Ltd.


Zhang Y.,Blood Diseases Hospital | Zhang Y.,Chinese Academy of Sciences | Hu T.,Blood Diseases Hospital | Hu T.,Chinese Academy of Sciences | And 24 more authors.
PLoS ONE | Year: 2014

The development of early B cells, which are generated from hematopoietic stem cells (HSCs) in a series of well-characterized stages in bone marrow (BM), represents a paradigm for terminal differentiation processes. Akt is primarily regulated by phosphorylation at Thr308 by PDK1 and at Ser473 by mTORC2, and Akt signaling plays a key role in hematopoiesis. However, the role of mTORC2 in the development of early B cells remains poorly understood. In this study, we investigated the functional role of mTORC2 by specifically deleting an integral component, Rictor, in a hematopoietic system. We demonstrated that the deletion of Rictor induced an aberrant increase in the FoxO1 and Rag-1 proteins in BM B cells and that this increase was accompanied by a significant decrease in the abundance of B cells in the peripheral blood (PB) and the spleen, suggesting impaired development of early B cells in adult mouse BM. A BM transplantation assay revealed that the B cell differentiation defect induced by Rictor deletion was not affected by the BM microenvironment, thus indicating a cell-intrinsic mechanism. Furthermore, the knockdown of FoxO1 in Rictor-deleted HSCs and hematopoietic progenitor cells (HPCs) promoted the maturation of B cells in the BM of recipient mice. In addition, we revealed that treatment with rapamycin (an mTORC1 inhibitor) aggravated the deficiency in B cell development in the PB and BM. Taken together, our results provide further evidence that Rictor regulates the development of early B cells in a cell-intrinsic manner by modifying the expression of FoxO1 and Rag-1. © 2014 Zhang et al.


Liu Y.,Hospital of Academy of Military Medical science | Liu B.,Hospital of Academy of Military Medical science | Li X.-Y.,Hospital of Academy of Military Medical science | Li J.-J.,Hospital of Academy of Military Medical science | And 8 more authors.
Journal of Experimental and Clinical Cancer Research | Year: 2011

Background: Epidermal growth factor receptor (EGFR) mutation is strongly associated with the therapeutic effect of tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC). Nevertheless, tumor tissue that needed for mutation analysis is frequently unavailable. Body fluid was considered to be a feasible substitute for the analysis, but arising problems in clinical practice such as relatively lower mutation rate and poor clinical correlation are not yet fully resolved. Method. In this study, 50 patients (32 pleural fluids and 18 plasmas) with TKIs therapy experience and with direct sequencing results were selected from 220 patients for further analysis. The EGFR mutation status was re-evaluated by Amplification Refractory Mutation System (ARMS), and the clinical outcomes of TKIs were analyzed retrospectively. Results: As compared with direct sequencing, 16 positive and 23 negative patients were confirmed by ARMS, and the other 11 former negative patients (6 pleural fluids and 5 plasmas) were redefined as positive, with a fairly well clinical outcome (7 PR, 3 SD, and 1 PD). The objective response rate (ORR) of positive patients was significant, 81.3% (direct sequencing) and 72.7% (ARMS) for pleural fluids, and 80% (ARMS) for plasma. Notably, even reclassified by ARMS, the ORR for negative patients was still relatively high, 60% for pleural fluids and 46.2% for plasma. Conclusions: When using body fluids for EGFR mutation analysis, positive result is consistently a good indicator for TKIs therapy, and the predictive effect was no less than that of tumor tissue, no matter what method was employed. However, even reclassified by ARMS, the correlation between negative results and clinical outcome of TKIs was still unsatisfied. The results indicated that false negative mutation still existed, which may be settled by using method with sensitivity to single DNA molecule or by optimizing the extraction procedure with RNA or CTC to ensure adequate amount of tumor-derived nucleic acid for the test. © 2011 Liu et al; licensee BioMed Central Ltd.


Li C.,Hospital of Academy of Military Medical science
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology | Year: 2011

Mesenchymal stem cells (MSC) are a kind of non-hematopoietic adult stem cells with highly self-renewal and multilineage differentiation potential. Because MSC can be easily obtained and expanded in large amount in vitro, they have become a hot field of stem cell research in recent years. MSC as a seed carrier of cells and gene therapy have been widely used in cardiovascular, nervous, respiratory diseases, wound healing and other aspects in clinic. But some biological characteristics and the molecular control mechanisms of MSC are not very clear and need further explorations. The MSC isolated and cultured in vitro are a type of multipotent differentiation cells, which differentiation potential in vivo has still uncertained, the effectiveness and safety such as gene mutations and canceration in vivo remains to be explored. Deepgoing studys on homing characteristics, mechanisms and influence factors of MSC also contribute to the clinical application, and the studys on the MSC differentiation fate in microenvironment in vivo would be better for clinical application. So how stably and efficiently label MSC in vitro is the key problem to monitoring the survival, migration, distribution, proliferation and differentiation of MSC in vivo. This review summarizes the current progress of study on the new labeling methods in vitro of MSC, discussing the advantages and disadvantages of different in vitro labeling methods and application of appropriate conditions.


PubMed | Hospital of Academy of Military Medical science
Type: Journal Article | Journal: Zhongguo shi yan xue ye xue za zhi | Year: 2011

Mesenchymal stem cells (MSC) are a kind of non-hematopoietic adult stem cells with highly self-renewal and multilineage differentiation potential. Because MSC can be easily obtained and expanded in large amount in vitro, they have become a hot field of stem cell research in recent years. MSC as a seed carrier of cells and gene therapy have been widely used in cardiovascular, nervous, respiratory diseases, wound healing and other aspects in clinic. But some biological characteristics and the molecular control mechanisms of MSC are not very clear and need further explorations. The MSC isolated and cultured in vitro are a type of multipotent differentiation cells, which differentiation potential in vivo has still uncertained, the effectiveness and safety such as gene mutations and canceration in vivo remains to be explored. Deepgoing studys on homing characteristics, mechanisms and influence factors of MSC also contribute to the clinical application, and the studys on the MSC differentiation fate in microenvironment in vivo would be better for clinical application. So how stably and efficiently label MSC in vitro is the key problem to monitoring the survival, migration, distribution, proliferation and differentiation of MSC in vivo. This review summarizes the current progress of study on the new labeling methods in vitro of MSC, discussing the advantages and disadvantages of different in vitro labeling methods and application of appropriate conditions.

Loading Hospital of Academy of Military Medical science collaborators
Loading Hospital of Academy of Military Medical science collaborators